Tumor necrosis factor–like weak inducer of apoptosis is a mitogen for liver progenitor cells

Janina E. E. Tirnitz‐Parker, Cornelia S. Viebahn, Aniela Jakubowski, Borut R. S. Klopcic, John K. Olynyk, George C. T. Yeoh, Belinda Knight – 23 June 2010 – Liver progenitor cells (LPCs) represent the cell compartment facilitating hepatic regeneration during chronic injury while hepatocyte‐mediated repair mechanisms are compromised. LPC proliferation is frequently observed in human chronic liver diseases such as hereditary hemochromatosis, fatty liver disease, and chronic hepatitis.

Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection

Nabora Soledad Reyes de Mochel, Scott Seronello, Shelley Hsiuying Wang, Chieri Ito, Jasper Xi Zheng, T. Jake Liang, J. David Lambeth, Jinah Choi – 23 June 2010 – Oxidative stress has been identified as a key mechanism of hepatitis C virus (HCV)–induced pathogenesis. Studies have suggested that HCV increases the generation of hydroxyl radical and peroxynitrite close to the cell nucleus, inflicting DNA damage, but the source of reactive oxygen species (ROS) remains incompletely characterized.

Erratum: Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development

Thomas Touboul, Nicholas R. F. Hannan, Sébastien Corbineau, Amélie Martinez, Clémence Martinet, Sophie Branchereau, Sylvie Mainot, Hélène Strick‐Marchand, Roger Pedersen, James Di Santo, Anne Weber, Ludovic Vallier – 23 June 2010

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: A meta‐analysis of the risk factors

Mariana Verdelho Machado, António Gouveia Oliveira, Helena Cortez‐Pinto – 23 June 2010 – Hepatic steatosis (HS) is frequent in patients with hepatitis C virus (HCV) infection, occurring in 40%‐80%, associating with metabolic and virus‐related factors, namely, genotype 3 and viral load. Human immunodeficiency virus (HIV) infection and antiretroviral treatment seem to be risk factors for HS. Several studies addressed this issue in coinfected patients, with discrepant results. A meta‐analysis was performed on the HS risk factors in coinfected patients.

Bile acid changes after high‐dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression

Emmanouil Sinakos, Hanns‐Ulrich Marschall, Kris V. Kowdley, Alex Befeler, Jill Keach, Keith Lindor – 23 June 2010 – High‐dose (28‐30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve survival and is associated with increased rates of serious adverse events. The mechanism for the latter undesired effect remains unclear.

Activation of Rac1 promotes hedgehog‐mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells

Steve S. Choi, Rafal P. Witek, Liu Yang, Alessia Omenetti, Wing‐Kin Syn, Cynthia A. Moylan, Youngmi Jung, Gamze F. Karaca, Vanessa S. Teaberry, Thiago A. Pereira, Jiangbo Wang, Xiu‐Rong Ren, Anna Mae Diehl – 23 June 2010 – Hepatic accumulation of myofibroblastic hepatic stellate cells (MF‐HSCs) is pivotal in the pathogenesis of cirrhosis. Two events are necessary for MF‐HSCs to accumulate in damaged livers: transition of resident, quiescent hepatic stellate cells (Q‐HSCs) to MF‐HSCs and expansion of MF‐HSC numbers through increased proliferation and/or reduced apoptosis.

Macroautophagy and chaperone‐mediated autophagy are required for hepatocyte resistance to oxidant stress

Yongjun Wang, Rajat Singh, Youqing Xiang, Mark J. Czaja – 23 June 2010 – The function of the lysosomal degradative pathway of autophagy in cellular injury is unclear, because findings in nonhepatic cells have implicated autophagy as both a mediator of cell death and as a survival response. Autophagic function is impaired in steatotic and aged hepatocytes, suggesting that in these settings hepatocellular injury may be altered by the decrease in autophagy.

Fitness versus fatness: Moving beyond weight loss in nonalcoholic fatty liver disease

Nathan A. Johnson, Jacob George – 23 June 2010 – The rapid emergence of nonalcoholic fatty liver disease (NAFLD) as a cause of both liver‐related morbidity and mortality and cardiometabolic risk has led to the search for effective lifestyle strategies to reduce liver fat. Lifestyle intervention comprising dietary restriction in conjunction with increased physical activity has shown clear hepatic benefits when weight loss approximating 3%‐10% of body weight is achieved.

Subscribe to